Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pleural Effusion, Malignant Adenocarcinoma Adenoma Adnexal Diseases Anus Diseases Anus Neoplasms Appendiceal Neoplasms Ascites Ascites, Malignant Breast Diseases Breast Neoplasms Bronchial Neoplasms Carcinoma Carcinoma Bladder Carcinoma Breast Carcinoma of Esophagus Carcinoma of Unknown Primary Carcinoma of the Anus Carcinoma of the Appendix Carcinoma of the Bladder Carcinoma of the Cervix Carcinoma of the Head and Neck Carcinoma of the Larynx Carcinoma of the Nasopharynx Carcinoma of the Oral Cavity Carcinoma of the Oropharynx Carcinoma of the Penis Carcinoma of the Vulva Carcinoma, Bronchogenic Carcinoma, Ductal Carcinoma, Hepatocellular Carcinoma, Neuroendocrine Carcinoma, Non-Small-Cell Lung Carcinoma, Ovarian Carcinoma, Pancreatic Carcinoma, Pancreatic Ductal Carcinoma, Renal Carcinoma, Renal Cell Carcinoma, Small Cell Carcinoma, Thymic Cecal Diseases Cecal Neoplasms Cholangiocarcinoma Colonic Diseases Colonic Neoplasms Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Esophageal Diseases Esophageal Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Gastrointestinal Diseases Gastrointestinal Neoplasms Gastrointestinal Stromal Tumors Genital Diseases Genital Diseases, Female Genital Diseases, Male Genital Neoplasms, Female Genital Neoplasms, Male Gonadal Disorders Head and Neck Neoplasms Hemic and Lymphatic Diseases Intestinal Diseases Intestinal Neoplasms Kidney Diseases Kidney Neoplasms Laryngeal Diseases Laryngeal Neoplasms Liver Diseases Liver Neoplasms Lung Diseases Lung Neoplasms Lymphatic Diseases Male Urogenital Diseases Melanoma Mesothelioma Mouth Diseases Mouth Neoplasms Nasopharyngeal Diseases Nasopharyngeal Neoplasms Neoplasm Metastasis Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Complex and Mixed Neoplasms, Connective Tissue Neoplasms, Connective and Soft Tissue Neoplasms, Ductal, Lobular, and Medullary Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Mesothelial Neoplasms, Nerve Tissue Neoplasms, Unknown Primary Neoplastic Processes Neuroectodermal Tumors Neuroendocrine Tumors Nevi and Melanomas Oropharyngeal Neoplasms Otorhinolaryngologic Diseases Otorhinolaryngologic Neoplasms Ovarian Diseases Ovarian Neoplasms Pancreatic Cancer Pancreatic Diseases Pancreatic Neoplasms Pathologic Processes Pathological Conditions, Signs and Symptoms Penile Diseases Penile Neoplasms Pharyngeal Diseases Pharyngeal Neoplasms Pleural Diseases Pleural Effusion Pleural Neoplasms Rectal Diseases Rectal Neoplasms Respiratory Tract Diseases Respiratory Tract Neoplasms Skin Diseases Skin Neoplasms Skin and Connective Tissue Diseases Stomach Diseases Stomach Neoplasms Stomatognathic Diseases Thoracic Neoplasms Thymoma Thymus Neoplasms Urinary Bladder Diseases Urinary Bladder Neoplasms Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms Uterine Cervical Diseases Uterine Cervical Neoplasms Uterine Diseases Uterine Neoplasms Vulvar Diseases Vulvar Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

xCures

Oakland, California, 94612, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient is ≥18 years of age
Written Informed Consent provided by patient
Diagnosis of any kind of carcinoma
Malignant fluid (e.g. pleural effusion or ascites) drainage OR tumor tissue resection OR tumor tissue needle biopsy is clinically indicated as part of SOC
Proceeding onto therapy for treatment
Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088)

Exclusion criteria

Lack of informed consent
Unable to obtain sufficient sample

Treatment and study plan

Primary outcomes

BOR

Time frame: 12 months

Best overall response

Secondary outcomes

PFS

Time frame: 24 months

Progression Free Survival

Sponsors and collaborators

Lead sponsor

Travera Inc

Industry

Collaborators

xCures

Registry information

Official study title

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance

Acronym: TraveraRTGx

Important dates

Study start: 2022
Primary completion: 2026
Study completion: 2026
First posted: Jul 18, 2022
Registry last updated: Apr 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed